VOR
USDVor Biopharma Inc. Common Stock
实时价格
价格图表
关键指标
市场指标
开盘价
$21.960
最高价
$22.000
最低价
$19.620
成交量
0.22M
公司基本面
市值
140.9M
所属行业
生物技术
国家/地区
United States
交易统计
平均成交量
0.36M
交易所
NMS
货币
USD
52周价格范围
相关新闻
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, the Compensation
HC Wainwright & Co. Maintains Buy on Vor Biopharma, Raises Price Target to $52
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Vor Biopharma with a Buy and raises the price target from $3 to $52.
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to
Baird Upgrades Vor Biopharma to Outperform, Raises Price Target to $64
Baird analyst Jack Allen upgrades Vor Biopharma from Neutral to Outperform and raises the price target from $20 to $64.
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-point ESSDAI (EULAR
